
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
According to the recently published report 'Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update'; Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 37 molecules.
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation.
The report outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 6, 9, 2, 12 and 6 respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Dermatology, Musculoskeletal Disorders, Oncology, Central Nervous System, Infectious Disease, Respiratory, Metabolic Disorders, Ophthalmology and Undisclosed which include indications Autoimmune Disorders, Psoriasis, Systemic Lupus Erythematosus, Plaque Psoriasis (Psoriasis Vulgaris), Inflammatory Bowel Disease, Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Psoriatic Arthritis, Ulcerative Colitis, Inflammation, Unspecified Immunological Disorders, Asthma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Crohn's Disease (Regional Enteritis), Dermatomyositis, Multiple Sclerosis, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Alopecia Areata, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Obstructive Pulmonary Disease (COPD), Chronic Urticaria Or Hives, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Enteritis, Fibrosis, Follicular Lymphoma, Hidradenitis Suppurativa, Intermediate Uveitis, Kidney Cancer (Renal Cell Cancer), Lupus Erythematosus, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Neuroinflammation, Non-infectious Uveitis, Pancreatic Cancer, Panuveitis, Peripheral T-Cell Lymphomas (PTCL), Posterior Uveitis, Skin Cancer, Solid Tumor, Subacute Cutaneous Lupus Erythematosus (SCLE), Unspecified, Unspecified B-Cell Lymphomas, Unspecified Dermatological Disorders, Vitiligo and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
According to the recently published report 'Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update'; Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 37 molecules.
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation.
The report outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 6, 9, 2, 12 and 6 respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Dermatology, Musculoskeletal Disorders, Oncology, Central Nervous System, Infectious Disease, Respiratory, Metabolic Disorders, Ophthalmology and Undisclosed which include indications Autoimmune Disorders, Psoriasis, Systemic Lupus Erythematosus, Plaque Psoriasis (Psoriasis Vulgaris), Inflammatory Bowel Disease, Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Psoriatic Arthritis, Ulcerative Colitis, Inflammation, Unspecified Immunological Disorders, Asthma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Crohn's Disease (Regional Enteritis), Dermatomyositis, Multiple Sclerosis, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Alopecia Areata, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Obstructive Pulmonary Disease (COPD), Chronic Urticaria Or Hives, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Enteritis, Fibrosis, Follicular Lymphoma, Hidradenitis Suppurativa, Intermediate Uveitis, Kidney Cancer (Renal Cell Cancer), Lupus Erythematosus, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Neuroinflammation, Non-infectious Uveitis, Pancreatic Cancer, Panuveitis, Peripheral T-Cell Lymphomas (PTCL), Posterior Uveitis, Skin Cancer, Solid Tumor, Subacute Cutaneous Lupus Erythematosus (SCLE), Unspecified, Unspecified B-Cell Lymphomas, Unspecified Dermatological Disorders, Vitiligo and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
- The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
124 Pages
- Introduction
- Global Markets Direct Report Coverage
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Overview
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Companies Involved in Therapeutics Development
- A2A Pharmaceuticals Inc
- Alexion Pharmaceuticals Inc
- Alumis Inc
- Amgen Inc
- Atomwise Inc
- BeiGene Ltd
- Bristol-Myers Squibb Co
- Galapagos NV
- Haisco Pharmaceutical Group Co Ltd
- InnoCare Pharma Ltd
- Kinaset Therapeutics Inc
- Merck & Co Inc
- Neuron23 Inc
- Nimbus Therapeutics LLC
- Oncostellae SL
- Pfizer Inc
- Priovant Therapeutics Inc
- Sareum Holdings Plc
- Shenzhen Chipscreen Biosciences Co Ltd
- Simcere Pharmaceutical Group Ltd
- Sudo Biosciences Inc
- Technoderma Medicines Inc
- Theravance Biopharma Inc
- Ventyx Biosciences Inc
- Xilingyuan Pharmaceutical Co Ltd
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Drug Profiles
- A2A-I-01 – Drug Profile
- BGB-23339 – Drug Profile
- BMS-986322 – Drug Profile
- brepocitinib tosylate – Drug Profile
- cerdulatinib – Drug Profile
- CS-43001 – Drug Profile
- deucravacitinib – Drug Profile
- ESK-001 – Drug Profile
- FTP-637 – Drug Profile
- GLPG-3667 – Drug Profile
- ICP-332 – Drug Profile
- ICP-488 – Drug Profile
- KN-002 – Drug Profile
- NDI-031407 – Drug Profile
- NDI-034858 – Drug Profile
- Oral TYK2 (JH2) – Drug Profile
- OST-122 – Drug Profile
- QY-201 – Drug Profile
- SAR-20347 – Drug Profile
- SDC-1801 – Drug Profile
- SDC-1802 – Drug Profile
- Small Molecule to Inhibit JAK1 and TYK2 for Rheumatoid Arthritis – Drug Profile
- Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema – Drug Profile
- Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma – Drug Profile
- Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis – Drug Profile
- Small Molecule to Inhibit TYK2 for Inflammatory Disorders and Neuroinflammation – Drug Profile
- Small Molecule to Inhibit TYK2 for Unspecified Immunological Disorders – Drug Profile
- Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology – Drug Profile
- Small Molecules to Inhibit TYK2 for Inflammation – Drug Profile
- SMP-117 – Drug Profile
- TDM-180935 – Drug Profile
- TDMSLE-01 – Drug Profile
- TLL-018 – Drug Profile
- TYK2 (JH2) Program 2 – Drug Profile
- TYK2 (JH2) Program 3 – Drug Profile
- TYK2 (JH2) Program 4 – Drug Profile
- VTX-958 – Drug Profile
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Dormant Products
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Discontinued Products
- Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Product Development Milestones
- Featured News & Press Releases
- Nov 08, 2022: Sareum Holdings : Update on SDC-1801 CTA application
- Sep 28, 2022: Alumis announces initiation of patient dosing in phase 2 clinical trial of ESK-001 for the treatment of plaque psoriasis
- Sep 12, 2022: Bristol Myers Squibb announces new Sotyktu (deucravacitinib) long-term data showing clinical efficacy maintained for up to two years with continuous treatment in moderate-to-severe plaque psoriasis
- Sep 09, 2022: US FDA grants approval for BMS’ Sotyktu to treat plaque psoriasis
- Aug 24, 2022: Nimbus Therapeutics presents new data on oral allosteric TYK2 inhibitor at American Chemical Society Meeting
- Aug 15, 2022: Ventyx Biosciences announces positive topline phase 1 data for its selective allosteric TYK2 inhibitor VTX95
- Aug 11, 2022: Ventyx Biosciences to report topline results from the phase 1 trial of its TYK 2 inhibitor VTX958 and second quarter 2022 financial results on August 15, 2022
- Aug 02, 2022: InnoCare announces first subject dosed in clinical trial of TYK2 JH2 allosteric inhibitor ICP-488 in China
- Jul 28, 2022: Sareum submits clinical trial authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an operational update
- Jun 28, 2022: Roivant and Pfizer unveil Priovant Therapeutics and ongoing registrational studies for oral Brepocitinib in dermatomyositis and lupus
- Jun 01, 2022: Late-Breaking data at EULAR 2022 demonstrate deucravacitinib significantly improved disease activity in phase 2 PAISLEY study in Systemic Lupus Erythematosus
- Jun 01, 2022: Lupus Research Alliance and Lupus Therapeutics response to positive data from phase 2 study on potential first-in-class lupus treatment
- May 19, 2022: Nimbus Therapeutics presents additional clinical data from phase 1 studies of oral allosteric TYK2 inhibitor at SID Annual Meeting
- May 12, 2022: New two-year deucravacitinib data reinforce durable efficacy and consistent safety profile in treatment of moderate to severe plaque psoriasis
- Apr 11, 2022: European patent granted for Sareum's SDC-1802, a novel small molecule TYK2/JAK1 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development by Stage of Development, 2022
- Table 2: Number of Products under Development by Therapy Areas, 2022
- Table 3: Number of Products under Development by Indications, 2022
- Table 4: Number of Products under Development by Indications, 2022 (Contd..1)
- Table 5: Number of Products under Development by Indications, 2022 (Contd..2)
- Table 6: Number of Products under Development by Companies, 2022
- Table 7: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022
- Table 9: Products under Development by Companies, 2022 (Contd..1)
- Table 10: Products under Development by Companies, 2022 (Contd..2)
- Table 11: Products under Development by Companies, 2022 (Contd..3)
- Table 12: Products under Development by Companies, 2022 (Contd..4)
- Table 13: Products under Development by Companies, 2022 (Contd..5)
- Table 14: Products under Development by Companies, 2022 (Contd..6)
- Table 15: Number of Products by Stage and Mechanism of Actions, 2022
- Table 16: Number of Products by Stage and Route of Administration, 2022
- Table 17: Number of Products by Stage and Molecule Type, 2022
- Table 18: Pipeline by A2A Pharmaceuticals Inc, 2022
- Table 19: Pipeline by Alexion Pharmaceuticals Inc, 2022
- Table 20: Pipeline by Alumis Inc, 2022
- Table 21: Pipeline by Amgen Inc, 2022
- Table 22: Pipeline by Atomwise Inc, 2022
- Table 23: Pipeline by BeiGene Ltd, 2022
- Table 24: Pipeline by Bristol-Myers Squibb Co, 2022
- Table 25: Pipeline by Galapagos NV, 2022
- Table 26: Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022
- Table 27: Pipeline by InnoCare Pharma Ltd, 2022
- Table 28: Pipeline by Kinaset Therapeutics Inc, 2022
- Table 29: Pipeline by Merck & Co Inc, 2022
- Table 30: Pipeline by Neuron23 Inc, 2022
- Table 31: Pipeline by Nimbus Therapeutics LLC, 2022
- Table 32: Pipeline by Oncostellae SL, 2022
- Table 33: Pipeline by Pfizer Inc, 2022
- Table 34: Pipeline by Priovant Therapeutics Inc, 2022
- Table 35: Pipeline by Sareum Holdings Plc, 2022
- Table 36: Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
- Table 37: Pipeline by Simcere Pharmaceutical Group Ltd, 2022
- Table 38: Pipeline by Sudo Biosciences Inc, 2022
- Table 39: Pipeline by Technoderma Medicines Inc, 2022
- Table 40: Pipeline by Theravance Biopharma Inc, 2022
- Table 41: Pipeline by Ventyx Biosciences Inc, 2022
- Table 42: Pipeline by Xilingyuan Pharmaceutical Co Ltd, 2022
- Table 43: Dormant Products, 2022
- Table 44: Dormant Products, 2022 (Contd..1)
- Table 45: Dormant Products, 2022 (Contd..2)
- Table 46: Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development by Stage of Development, 2022
- Figure 2: Number of Products under Development by Therapy Areas, 2022
- Figure 3: Number of Products under Development by Top 10 Indications, 2022
- Figure 4: Number of Products by Stage and Mechanism of Actions, 2022
- Figure 5: Number of Products by Routes of Administration, 2022
- Figure 6: Number of Products by Stage and Routes of Administration, 2022
- Figure 7: Number of Products by Stage and Molecule Type, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.